MedTrace Logo

Study of STLX-2012 in Healthy Volunteers

NCT07231744 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.

Conditions

  • Healthy Participants

Interventions

DRUG

STLX-2012

STLX-2012 IV

OTHER

Placebo

Placebo arm

Sponsors & Collaborators

  • Stelexis BioSciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07231744 on ClinicalTrials.gov